Literature DB >> 22692568

Chronic Δ⁹-tetrahydrocannabinol exposure induces a sensitization of dopamine D₂/₃ receptors in the mesoaccumbens and nigrostriatal systems.

Nathalie Ginovart1, Benjamin B Tournier, Marcelle Moulin-Sallanon, Thierry Steimer, Vicente Ibanez, Philippe Millet.   

Abstract

Δ⁹-tetrahydrocannabinol (THC), through its action on cannabinoid type-1 receptor (CB₁R), is known to activate dopamine (DA) neurotransmission. Functional evidence of a direct antagonistic interaction between CB₁R and DA D₂-receptors (D₂R) suggests that D₂R may be an important target for the modulation of DA neurotransmission by THC. The current study evaluated, in rodents, the effects of chronic exposure to THC (1 mg/kg/day; 21 days) on D₂R and D₃R availabilities using the D₂R-prefering antagonist and the D₃R-preferring agonist radiotracers [¹⁸F]fallypride and [³H]-(+)-PHNO, respectively. At 24 h after the last THC dose, D₂R and D₃R densities were significantly increased in midbrain. In caudate/putamen (CPu), THC exposure was associated with increased densities of D₂R with no change in D₂R mRNA expression, whereas in nucleus accumbens (NAcc) both D₃R binding and mRNA levels were upregulated. These receptor changes, which were completely reversed in CPu but only partially reversed in NAcc and midbrain at 1 week after THC cessation, correlated with an increased functionality of D₂/₃R in vivo, based on findings of increased locomotor suppressive effect of a presynaptic dose and enhanced locomotor activation produced by a postsynaptic dose of quinpirole. Concomitantly, the observations of a decreased gene expression of tyrosine hydroxylase in midbrain together with a blunted psychomotor response to amphetamine concurred to indicate a diminished presynaptic DA function following THC. These findings indicate that the early period following THC treatment cessation is associated with altered presynaptic D₂/₃R controlling DA synthesis and release in midbrain, with the concurrent development of postsynaptic D₂/₃R supersensitivity in NAcc and CPu. Such D₂/₃R neuroadaptations may contribute to the reinforcing and habit-forming properties of THC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22692568      PMCID: PMC3442351          DOI: 10.1038/npp.2012.91

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  74 in total

1.  Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry.

Authors:  P Mailleux; J J Vanderhaeghen
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

2.  Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study.

Authors:  P Mailleux; J J Vanderhaeghen
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

3.  Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains.

Authors:  M Lepore; X Liu; V Savage; D Matalon; E L Gardner
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

4.  Expression and pharmacological characterization of the human D3 dopamine receptor.

Authors:  S B Freedman; S Patel; R Marwood; F Emms; G R Seabrook; M R Knowles; G McAllister
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

5.  The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain.

Authors:  B H Westerink; H F Kwint; J B deVries
Journal:  J Neurosci       Date:  1996-04-15       Impact factor: 6.167

6.  Distribution volume ratios without blood sampling from graphical analysis of PET data.

Authors:  J Logan; J S Fowler; N D Volkow; G J Wang; Y S Ding; D L Alexoff
Journal:  J Cereb Blood Flow Metab       Date:  1996-09       Impact factor: 6.200

7.  Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain.

Authors:  T Kling-Petersen; E Ljung; K Svensson
Journal:  J Neural Transm Gen Sect       Date:  1995

8.  Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats.

Authors:  Z L Rossetti; Y Hmaidan; G L Gessa
Journal:  Eur J Pharmacol       Date:  1992-10-20       Impact factor: 4.432

9.  Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.

Authors:  F Rodríguez de Fonseca; M A Gorriti; J J Fernández-Ruiz; T Palomo; J A Ramos
Journal:  Pharmacol Biochem Behav       Date:  1994-01       Impact factor: 3.533

10.  Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic dopamine release.

Authors:  R Spanagel; O F Almeida; C Bartl; T S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

View more
  21 in total

1.  Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity.

Authors:  Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; David Alexoff; Jean Logan; Millard Jayne; Christopher Wong; Dardo Tomasi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction.

Authors:  Esmaeil Mansouri; José N Nobrega; Matthew N Hill; Rachel F Tyndale; Francis S Lee; Christian S Hendershot; Laura M Best; Patricia Di Ciano; Georgia Balsevich; Mathew E Sloan; Stephen J Kish; Junchao Tong; Bernard Le Foll; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2019-11-27       Impact factor: 7.853

Review 3.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

Review 4.  The effects of Δ9-tetrahydrocannabinol on the dopamine system.

Authors:  Michael A P Bloomfield; Abhishekh H Ashok; Nora D Volkow; Oliver D Howes
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

5.  Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use.

Authors:  Romina Mizrahi; Miran Kenk; Ivonne Suridjan; Isabelle Boileau; Tony P George; Kwame McKenzie; Alan A Wilson; Sylvain Houle; Pablo Rusjan
Journal:  Neuropsychopharmacology       Date:  2013-12-24       Impact factor: 7.853

6.  Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO.

Authors:  Romina Mizrahi; Ivonne Suridjan; Miran Kenk; Tony P George; Alan Wilson; Sylvain Houle; Pablo Rusjan
Journal:  Neuropsychopharmacology       Date:  2012-11-08       Impact factor: 7.853

7.  Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.

Authors:  Justine Renard; Michael Loureiro; Laura G Rosen; Jordan Zunder; Cleusa de Oliveira; Susanne Schmid; Walter J Rushlow; Steven R Laviolette
Journal:  J Neurosci       Date:  2016-05-04       Impact factor: 6.167

8.  Delineation of domains within the cannabinoid CB1 and dopamine D2 receptors that mediate the formation of the heterodimer complex.

Authors:  Shazina S Khan; Frank J S Lee
Journal:  J Mol Neurosci       Date:  2013-11-22       Impact factor: 3.444

9.  Genetic Predisposition vs Individual-Specific Processes in the Association Between Psychotic-like Experiences and Cannabis Use.

Authors:  Nicole R Karcher; Deanna M Barch; Catherine H Demers; David A A Baranger; Andrew C Heath; Michael T Lynskey; Arpana Agrawal
Journal:  JAMA Psychiatry       Date:  2019-01-01       Impact factor: 21.596

Review 10.  Social Stress and Psychosis Risk: Common Neurochemical Substrates?

Authors:  Romina Mizrahi
Journal:  Neuropsychopharmacology       Date:  2015-09-09       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.